Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study) - PubMed
6 hours ago
- #dapagliflozin
- #heart failure
- #real-world evidence
- Study on real-world evidence with dapagliflozin in HFrEF patients in Central Eastern Europe and the Baltic region.
- Multicentre, observational study across 9 countries with 1131 HFrEF patients included.
- High persistence rates of dapagliflozin (95-96% at 6-12 months), but low optimal dosing of other guideline-directed therapies.
- Common comorbidities included atrial fibrillation (46%), type 2 diabetes (37%), and chronic kidney disease (29%).
- Despite treatment persistence, improvement in HF management decisions in the region is needed.